• HOME
  • Advantages of Our Method

Aim

Immune monitoring for cancer patients

  1. Prediction of the effect of anti-PD-1 antibody before its administration

    ・Development of a diagnostic method to predict the effect of anti-PD-1 antibody before its administration
    This method has the advantages of not using cancer tissues, an inexpensive protocol, quick measurement and already finishing some clinical trials. The method calculating the value of X2/Y has been licensed out to Sysmex Corporation and Sysmex is developing a test reagent.

    ・Development of simpler diagnostic methods
    We will develop a method of easier sample handling.

    ・Patient stratification and clinical design
    Pharmaceutical companies will stratify patients and develop clinical designs when developing cancer treatments, especially in combination with immune checkpoint inhibitors.

    ・Acquisition of real-world data and accompanying tests in post-marketing surveillance
    To clarify the relationship between X2/Y value and the effects of post-marketing immune checkpoint inhibitors and concomitant drugs.

  2. Precision medicine for administration with immune checkpoint inhibitors
    ・Identification of immune cells that characterize various patient conditions
    Identify appropriate immunotherapy for individual patients.

  3. Companion diagnostics

    ・Discovery of new biomarkers
    We will search for biomarkers for development of novel drugs and develop companion diagnostics.

  4. Database

    ・Monitor immune cells involved in inflammation and find relationship of them with many disease states. These data will be utilized for developing diagnostic, therapeutic and prophylactic methods
    We will develop a method of treatment with immune cells so that the effect of anti-PD-1 antibody can be obtained more easily.

Immune cell therapy for cancer

Immune cell therapy

We will develop a method of treatment with immune cells so that the effect of anti-PD-1 antibody can be obtained more easily.


Immune monitoring for patients with diseases other than cancer

Monitor immune cells of patients with diseases other than cancer. We try to develop diagnostic, therapeutic and prophylactic methods

We will develop methods of immunodiagnosis and immunotherapy.